On October 14, Bristol-Myers Squibb announced that the combination immunotherapy of Opdivo (nivolumab injection) and Yervoy (ipilimumab injection) has been approved by the China National Medical Products Administration (NMPA) for new indications, suitable for first-line treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer (CRC) patients. This approval marks the first official approval by health regulatory authorities worldwide.
百时美施贵宝：欧狄沃与逸沃双免疫联合疗法新适应症在华获批
Bristol-Myers Squibb: Opdivo and Yervoy dual immunotherapy new indications approved in China
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated